M
Midori Nakagaki
Researcher at Royal Brisbane and Women's Hospital
Publications - 14
Citations - 115
Midori Nakagaki is an academic researcher from Royal Brisbane and Women's Hospital. The author has contributed to research in topics: Transplantation & Internal medicine. The author has an hindex of 5, co-authored 11 publications receiving 89 citations.
Papers
More filters
Journal ArticleDOI
Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation
TL;DR: The results indicate that oral RBV has clinical efficacy in the treatment of RSV/PIV3 infection post HPCT, however, a starting dose of 10 mg/kg/day appears ineffective; it is recommended to recommend aStarting dose of 20mg/ kg/day in this patient group.
Journal ArticleDOI
Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis
TL;DR: The outcome of consecutive adult patients diagnosed with ALL and treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD) at this institution between May 2005 and December 2010 is reviewed.
Journal ArticleDOI
Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations
Andras Farkas,Gergely Daróczi,Phillip Villasurda,Michael J. Dolton,Midori Nakagaki,Jason A. Roberts +5 more
TL;DR: While simulations with the linear model were found to be slightly more accurate and similarly precise, the small difference in accuracy is likely negligible from the clinical point of view, making all three approaches appropriate for use in a voriconazole TDM program.
Journal ArticleDOI
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
TL;DR: Olanzapine was an effective treatment of breakthrough CINV and a single dose of palonosetron significantly reduced nausea up to 24 h.
Journal ArticleDOI
Effect of plasmapheresis on ATG (Thymoglobulin) clearance prior to adoptive T cell transfer.
Ping Zhang,Cameron Curley,Kari Mudie,Midori Nakagaki,Geoffrey R. Hill,Geoffrey R. Hill,Jason A. Roberts,Siok-Keen Tey,Siok-Keen Tey,Siok-Keen Tey +9 more
TL;DR: Active rabbit ATG concentration is measured using a flow cytometry-based method that can be implemented in any laboratory and likely has modest biological impact when performed 4 weeks after 6 mg/kg ATG.